Startup profile · funding coverage
AnaCardio funding, valuation and investors
Clinical-stage cardiovascular biotech developing AC01, an oral ghrelin-receptor agonist for chronic advanced heart failure.
Keep track of AnaCardio
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
€62.5M · September 30, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · Stockholm, Sweden
Investors in latest funding
Lead: Novo Holdings , Ljungström family office
Other: Helsinn , Pureos Bioventures , Sound Bioventures , Industrifonden , Flerie , LLD Nybohov Invest AB , Innovestor Life Science
Overview
AnaCardio is a Stockholm clinical-stage biopharmaceutical company founded on research from Karolinska Institutet. Its lead program, AC01, is an in-licensed oral ghrelin-mimetic small molecule intended to improve cardiac contractility without the safety limitations associated with conventional intravenous inotropes. A €62.5 million Series B announced September 30, 2026 is intended to fully fund the GOAL-HF2 Phase 2b study.
Why AnaCardio is interesting
AnaCardio's €62.5 million Series B fully funds a roughly 400-patient Phase 2b trial designed with FDA and EMA input, moving a differentiated oral contractility drug toward Phase 3 readiness.
Product & use cases
AC01 is a first-in-class oral ghrelin receptor agonist and calcium-sensitizing contractile agent for patients with chronic advanced heart failure with reduced ejection fraction. GOAL-HF2 is planned as a randomized, double-blind, placebo-controlled Phase 2b trial in approximately 400 patients across about 100 sites in 12 countries.
- Potential chronic oral treatment for advanced HFrEF patients inadequately served by standard therapy
- Improving cardiac contractility without the tachycardia and arrhythmia risks associated with conventional inotropes
Key facts
- September 2026: completed €62.5M Series B
- GOAL-HF2 targets approximately 400 patients across 12 countries
- Company targets a Phase 3-ready asset by 2028
- Phase 1b/2a efficacy and safety observations require confirmation in later-stage trials
Funding history (newest first)
Series B
2026-09-30 €62.5M- Novo Holdings (lead)
- Ljungström family office (lead)
- Helsinn (participant)
- Pureos Bioventures (participant)
- Sound Bioventures (participant)
- Industrifonden (participant)
- Flerie (participant)
- LLD Nybohov Invest AB (participant)
- Innovestor Life Science (participant)
Investors in our directory
Funds linked from AnaCardio's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: AC01 combines an oral formulation with a differentiated ghrelin-signaling mechanism and has Phase 1b/2a proof-of-concept data published in The Lancet. The Series B is sized to reach a Phase 3-ready data package rather than another interim financing milestone.
AnaCardio must demonstrate that short-duration improvements in cardiac function translate into durable clinical benefit in a much larger and longer Phase 2b study. Conventional inotropes remain short-term hospital treatments, while other contractility programs and modern guideline-directed heart-failure therapies define the efficacy and safety bar.
-
Conventional intravenous inotropes incumbent
Dobutamine and milrinone can increase contractility but are generally restricted to short-term use because of safety concerns.
-
Cytokinetics adjacent
Has developed cardiac myosin activators aimed at improving cardiac function.
-
Windtree Therapeutics adjacent
Develops istaroxime-based therapy for acute heart failure and cardiogenic shock.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover AnaCardio's financing or category context.
FAQs about AnaCardio
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.